Skeletal Fragility in Type 2 Diabetes Mellitus

Area of Science:

• Endocrinology
• Orthopedics
• Metabolic Bone Disease

Background:

• Type 2 diabetes (T2D) is linked to elevated fracture risk, yet standard bone density measures underestimate this danger.
• Conventional fracture risk factors do not fully account for the heightened risk in T2D patients.
• Diabetic bone disease presents a complex challenge due to altered bone turnover and strength.

Purpose of the Study:

• To review the pathogenesis of increased fracture risk in Type 2 diabetes.
• To explore methods for detecting diabetic bone disease.
• To summarize current evidence on managing bone complications in T2D.

Main Methods:

• Literature review of epidemiological studies and research on bone metabolism in T2D.
• Analysis of factors contributing to bone microdamage and reduced bone strength.
• Evaluation of the role of specific biomarkers and medications.

Main Results:

• Osteocyte dysfunction leading to low bone turnover and microcracks is proposed as a key mechanism for T2D-related fractures.
• Elevated sclerostin levels may indicate low bone turnover and increased fracture risk.
• Certain antidiabetic drugs (glitazones, sulfonylureas) show detrimental effects on bone health.

Conclusions:

• Diabetic bone disease pathogenesis involves complex factors beyond bone mineral density, including impaired bone turnover and accumulation of advanced glycosylation endproducts.
• Sclerostin and impaired incretin response are potential contributors to fracture risk in T2D.
• Further research is needed for effective management strategies and guidelines for bone disease in T2D.